UBS maintained a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) but reduced its price target to $137 from $154, ...
The appointment of Dr. Keswani as CMO marks an important strategic move for Neurocrine Biosciences as the company enters an exciting and pivotal stage of its evolution. Today the company's shares ...
Neurocrine Biosciences, Inc. today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswani, an ...
Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO, April 4, 2025 /PRNewswire/ ...
Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds ...
Both 40 mg and 80 mg doses of INGREZZA showed substantial improvements in AIMS total scores, with mean baseline scores declining markedly by Week 48. The remission rates were consistent irrespective ...
(RTTNews) - Neurocrine Biosciences Inc. (NBIX), Thursday unveiled new data at the 2025 Psychiatry Update Conference in Chicago, highlighting the long-term efficacy of INGREZZA or valbenazine in ...
Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive dyskinesia through once-daily doses of Ingrezza (valbenazine). Post-hoc ...
Entrambe le dosi di INGREZZA, 40 mg e 80 mg, hanno mostrato miglioramenti sostanziali nei punteggi totali AIMS, con punteggi medi basali che sono diminuiti notevolmente entro la Settimana 48. I tassi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback